Imbria Pharmaceuticals has randomised the first participant in FORTITUDE HCM, a Phase IIb trial of ninerafaxstat in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback